CorMedix announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the creation, implementation and evaluation of initiatives that advance the Leapfrog and organizations’ alike mission for patient safety and promote a shared accountability for patient safety and well-being. As a Leapfrog partner, CorMedix will advise the Leapfrog board and management on industry and policy trends and help shape the organization’s long-term strategic vision. “An alliance between The Leapfrog Group and CorMedix brings together two organizations both focused on a common goal: improving patient safety and quality of care across the U.S. healthcare system,” said Joseph Todisco, Chief Executive Officer, CorMedix. “CorMedix is dedicated to developing solutions that reduce the risk of healthcare associated infections, in particular catheter-related bloodstream infections. About 250,000 CRBSIs occur annually among U.S. patients with an intravascular device, and one in four patients who acquire these infections die. It is important we all come together and advocate for patients who suffer from these preventable infections, in addition to managing their already challenging health conditions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRMD:
- Biotech Alert: Searches spiking for these stocks today
- CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
- CorMedix announces FDA approval of DefenCath
- CorMedix price target raised to $10 from $6 at RBC Capital
- CorMedix reports Q3 EPS (17c), consensus (21c)